Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid

Pharmacogenetics

Volumn 11, Issue 7, 2001, Pages 597-607

  Dai, D ^a   Zeldin, D C ^a   Blaisdell, J A ^a   Chanas, B ^a   Coulter, S J ^a   Ghanayem, B I ^a   Goldstein, J A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Arachidonic acid; CYP2C8 polymorphisms; Paclitaxel; Site directed mutagenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450 2C8; CYTOCHROME P450 ISOENZYME; PACLITAXEL; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SUBSTITUTION; ARACHIDONIC ACID METABOLISM; ARTICLE; ASIAN; CAUCASIAN; DRUG CLEARANCE; DRUG METABOLISM; ESCHERICHIA COLI; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; NEGRO; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARACHIDONIC ACID; ARYL HYDROCARBON HYDROXYLASES; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; METABOLIC CLEARANCE RATE; PACLITAXEL; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

ESCHERICHIA COLI;

EID: 0034791777     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200110000-00006     Document Type: Article

References (54)

1. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
2. Baculovirus expression of bovine cytochrome P450c17 in Sf9 cells and comparison with expression in yeast, mammalian cells, and E. coli
3. Lung cancer risk in relation to mephenytoin hydroxylation activity
4. A phase I trial of taxol given by a 6-hour intravenous infusion
5. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors
6. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid
7. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results
8. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
9. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
10. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
11. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans
12. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
13. Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets
14. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
15. Cytochrome P450 2C is an EDHF synthetase in coronary arteries
16. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry
17. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
18. Biochemistry and molecular biology of the human CYP2C subfamily
19. Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol
20. Metabolism of taxol by human hepatic microsomes and liver splices; participation of cytochrome P450 3A4 and an unknown P450 enzyme
21. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
22. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
23. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
24. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
25. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
26. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs
27. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol
28. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11
29. Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid
30. Cytochrome P-450 metabolism of arachidonic acid
31. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
32. Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes
33. P450 genes: Structure, evolution, and regulation
34. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids
35. The role of arachidonic acid and its metabolites in the release of neuropeptides
36. The carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature
37. Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma
38. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8
39. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli
40. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes
41. Cloning and expression of complementary DNAs for multiple members of the human cytochrome-P4502c subfamily
42. Variability in human cytochrome P450 paclitaxel metabolism
43. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1
44. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
45. Taxol metabolism and disposition in cancer patients
46. Plant antitumor agents, VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
47. Phase I clinical and pharmacokinetic study of taxol
48. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes
49. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
50. Possible involvement of arachidonic acid metabolites of cytochrome P450 monooxygenase pathway in vasopressin-stimulated glycogenolysis in isolated rat hepatocytes
51. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene
52. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform
53. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway
54. Optimizing high-dose therapy using pharmacokinetic principles